| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Andover, Mass. – September 10, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief ... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today report... |
| 21 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
WHEREAS, the Board and the shareholders of TransMedics Group, Inc. (the “Company”) approved and adopted the TransMedics Group, Inc. 2019 Stock Incentive Plan, as may be amended from time to time (the “Plan”), in 2019; and |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – May 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported ... |
| 27 Feb 2026 |
8-K: Results of Operations and Financial Condition
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – February 24, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today rep... |
| 04 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
THIS LEASE (this “Lease”) is entered into as of this 8th day of January, 2026 (the “Execution Date”), by and between BRE-BMR ASSEMBLY INNOVATION I LLC, a Delaware limited liability company (“Landlord”), and TRANSMEDICS GROUP, INC., a Mas... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – October 29, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today repo... |
| 06 Oct 2025 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by... |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – July 30, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reporte... |
| 23 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 22, 2025, TransMedics Group, Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders of the Company voted on the following proposals: |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – May 8, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported ... |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – February 27, 2025 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today rep... |
| 21 Feb 2025 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by... |
| 14 Jan 2025 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by... |
| 09 Dec 2024 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by... |
| 02 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Andover, Mass. – December 2, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today anno... |
| 28 Oct 2024 |
8-K: Results of Operations and Financial Condition
Andover, Mass. – October 28, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today repo... |
Loading...